Dicks Sporting Goods Inc vs Eli Lilly And Co — how do they compare? Dicks Sporting Goods Inc trades at $208.4 (market cap $18.92B), while Eli Lilly And Co trades at $1,155 (market cap $1.03T). The key difference: Eli Lilly And Co is far larger — about 54.4× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays the higher dividend (2.37%). Which is the better fit depends on your goals.
| DKS | LLY | |
|---|---|---|
Market Cap | $18.92B | $1.03T |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $1.24K |
52-Week Low | $187.78 | $625.65 |
Enterprise Value | $25.71B | $1.07T |
Dividend Yield | 2.37% | 0.6% |
Signals from Pluang's Aura AI — not financial advice
Dick's Sporting Goods (DKS) trades at $216.10, down 0.86% with a bearish technical outlook despite strong fundamentals. The company reported consistent earnings beats, with Q1 2026 EPS of $2.90 exceeding expectations, and maintains solid profitability with a 4.71% net margin. Recent developments include the launch of ScoreCard+ loyalty program and Lids partnership expansion. Analyst consensus remains strongly bullish with a $261 price target, though legal scrutiny over fiduciary duties presents near-term headwinds.
DKS offers attractive valuation with a P/E of 20.58 and P/S of 0.96, trading below analyst targets. Growth catalysts include market share gains and strategic partnerships, but risks involve competitive pressures and potential legal overhangs. The stock's current dip may present a buying opportunity for long-term investors given fundamental strength and institutional support.
Eli Lilly (LLY) trades at $1,185.08, down slightly (-0.29%) on the day, with a strong bullish technical signal from moving averages. The company demonstrates exceptional fundamental strength, with revenue surging to $65.18B in 2025 and a net income margin of 34.99%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive, with a consensus price target of $1,360.
The outlook for LLY remains robust, driven by its dominant position in the high-growth weight loss and Alzheimer's drug markets. Key opportunities include continued revenue expansion and pipeline advancements. Primary risks involve intensifying competition, particularly from Novo Nordisk's obesity pill, and the stock's premium valuation multiples, which demand sustained high growth to justify.
Trailing returns across standard periods
Latest headlines on both assets
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →